Mpox, once a rare virus mainly confined to parts of Central Africa, is rapidly evolving into a more serious global health ...

The live vaccine is produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.

Sierra Leone on Wednesday started injecting frontline health care workers and high-risk individuals and children from age 12 ...

Mpox has the potential to become a significant global health threat if taken too lightly, according to scientists at the University of Surrey.

The MVA-BN vaccine showed an overall effectiveness of 57.8% (95% CI, 11.8-83.0) in reducing mpox cases at 14 days or longer after the first dose; however, the effectiveness was lower in people ...

A new mutated variant of Mpox has been identified in Democratic Republic of Congo, with health authorities concerned over increased transmissibility. The new variant comes from the clade 1a strain ...

A study at Charité – Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose ...

WHO had declared an emergency for mpox in 2022. Such declarations pave the way for international efforts to curb the spread of the virus. Universiti Putra Malaysia consultant clinical ...

New data on Mpox vaccine effectiveness Date: March 19, 2025 Source: Charité - Universitätsmedizin Berlin Summary: A study has found that a single dose of the Imvanex vaccine provides protection ...